|
Rivera-Caravaca JM, Camelo-Castillo A, Ramirez-Macias I, Gil-Perez P, Lopez-Garcia C, Esteve-Pastor MA, Orenes-Pinero E, Tello-Montoliu A, Marin F. Antithrombotic Therapy in Patients with Peripheral Artery Disease: A Focused Review on Oral Anticoagulation. Int J Mol Sci. 2021 Jul 1;22(13):7113. doi: 10.3390/ijms22137113. PubMed PMID: 34281167; PubMed Central PMCID: PMC8267774.
AÑO: 2021; IF: 6.208
|
34281167
|
Proietti M, Vitolo M, Harrison SL, Lane DA, Fauchier L, Marin F, Nabauer M, Potpara TS, Dan GA, Boriani G, Lip GYH; ESC-EHRA EORP-AF Long-Term General Registry Investigators. Impact of clinical phenotypes on management and outcomes in European atrial fibrillation patients: a report from the ESC-EHRA EURObservational Research Programme in AF (EORP-AF) General Long-Term Registry. BMC Med. 2021 Oct 20;19(1):256. doi: 10.1186/s12916-021-02120-3. PubMed PMID: 34666757; PubMed Central PMCID: PMC8527730.
AÑO: 2021; IF: 11.15
|
|
Sanchez-Fuentes A, Rivera-Caravaca JM, Lopez-Galvez R, Marin F, Roldan V. Non-vitamin K Antagonist Oral Anticoagulants and Drug-Food Interactions: Implications for Clinical Practice and Potential Role of Probiotics and Prebiotics. Front Cardiovasc Med. 2022 Jan 17;8:787235. doi: 10.3389/fcvm.2021.787235. eCollection 2021. PubMed PMID: 35111826; PubMed Central PMCID: PMC8801490.
AÑO: 2021; IF: 5.846
|
|
SEC Working Group for the 2020 ESC Guidelines for the Management of Atrial Fibrillation; Expert Reviewers for the 2020 ESC Guidelines for the Management of Atrial Fibrillation; SEC Guidelines Committee; Working Group for the 2020 ESC guidelines for the management of atrial fibrillation; Expert reviewers for the 2020 ESC guidelines for the management of atrial fibrillation; SEC Guidelines Committee. Comments on the 2020 ESC/EACTS guidelines for the management of atrial fibrillation. Rev Esp Cardiol (Engl Ed). 2021 May;74(5):378-383. doi: 10.1016/j.rec.2020.11.023. Epub 2021 Mar 15. No abstract available. English, Spanish. PubMed PMID: 33736964.
AÑO: 2021
|
|
Van Mieghem NM, Unverdorben M, Hengstenberg C, Mollmann H, Mehran R, Lopez-Otero D, Nombela-Franco L, Moreno R, Nordbeck P, Thiele H, Lang I, Zamorano JL, Shawl F, Yamamoto M, Watanabe Y, Hayashida K, Hambrecht R, Meincke F, Vranckx P, Jin J, Boersma E, Rodes-Cabau J, Ohlmann P, Capranzano P, Kim HS, Pilgrim T, Anderson R, Baber U, Duggal A, Laeis P, Lanz H, Chen C, Valgimigli M, Veltkamp R, Saito S, Dangas GD; ENVISAGE-TAVI AF Investigators. Edoxaban versus Vitamin K Antagonist for Atrial Fibrillation after TAVR. N Engl J Med. 2021 Dec 2;385(23):2150-2160. doi: 10.1056/NEJMoa2111016. Epub 2021 Aug 28. PubMed PMID: 34449183.
AÑO: 2021; IF: 176.079
|